Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
Company Details
- Employees
- 29
- Address
- One Kendall Sq, Bldg. 200
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.delphiatx.com
- Keywords
- with Community Servings.
- HQ
- Cambridge, Massachusetts
Delphia Therapeutics Questions
Delphia Therapeutics's website is http://www.delphiatx.com
Delphia Therapeutics's LinkedIn profile is https://www.linkedin.com/company/delphia-therapeutics
Delphia Therapeutics has
29 employees.
View email and phone details for 29
employees at Delphia Therapeutics.
Delphia Therapeutics's industry is
Biotechnology Research
Delphia Therapeutics's top competitors are
Nuvalent, Inc.,
Quiver Bioscience,
Seaport Therapeutics,
Nona Biosciences,
Myrobalan Therapeutics,
Tessera Therapeutics,
Avalyn Pharma,
Fable Therapeutics,
Airna,
Kalvista Pharmaceuticals, Inc..
Delphia Therapeutics's categories are Biotechnology Research
